Generate Biomedicines (NASDAQ:GENB) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Generate Biomedicines (NASDAQ:GENB) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Several other equities analysts have also commented on GENB. Morgan Stanley upped their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. HC Wainwright lifted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Up 3.3%

GENB opened at $14.35 on Friday. The stock has a market cap of $1.84 billion and a PE ratio of -13.41. The company has a 50-day simple moving average of $14.45. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $18.18.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. Equities research analysts predict that Generate Biomedicines will post -2.29 EPS for the current year.

Institutional Trading of Generate Biomedicines

A hedge fund recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp bought a new position in shares of Generate Biomedicines Inc (NASDAQ:GENB) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,326 shares of the company’s stock, valued at approximately $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.